Miltenyi Biotec: Difference between revisions
131Platypi (talk | contribs) →Controversies: Removed multiple sources "padding up" the section, especially non noteable and biased ones. "lives saved" is non encyclopedic in this context. |
Arianwen88 (talk | contribs) #suggestededit-add 1.0 Tags: Mobile edit Mobile app edit Android app edit |
||
| Line 1: | Line 1: | ||
{{Short description|Global biotechnology company}} |
|||
{{advert|date=March 2018}} |
{{advert|date=March 2018}} |
||
{{Infobox company |
{{Infobox company |
||
Revision as of 10:12, 10 June 2023
 | This article contains promotional content. (March 2018) |
 | |
| Company type | Private |
|---|---|
| Industry | Biotechnology |
| Founded | 1989 |
| Founder | Stefan Miltenyi |
| Headquarters | , Germany |
Key people | Stefan Miltenyi, Founder & President Dr. Boris Stoffel, |
| Products | MACS Sample Preparation gentleMACS Dissociators |
Number of employees | ~3,000 |
| Website | www.miltenyibiotec.com |
Miltenyi Biotec is a global biotechnology company headquartered near Cologne in Bergisch Gladbach, Germany. The company is a provider of products and services that support scientists, clinical researchers, and physicians across basic research, translational research, and clinical applications. The company comes up with solutions[buzzword] covering techniques of sample preparation, cell separation, cell sorting, flow cytometry, cell culture, molecular analysis, clinical applications and small animal imaging. Miltenyi Biotec has more than 3,000 employees in 28 countries and more than 17,000 products.[citation needed]
Products
Miltenyi Biotec products have been cited in more than 20,000 publications and used in more than 35,000 clinical treatments to date. Many of the publications that have cited Miltenyi Biotec products can be accessed through CiteAb, an antibody search engine which lists 4591 Miltenyi Biotec products.[1] Miltenyi Biotec instruments, reagents and services support basic research, clinical research, and the translation of basic research findings into clinical applications that enhance human health and treat severe disease. Its product portfolio addresses a complete range of techniques from bench to bedside. Services offered by Miltenyi Biotec include gene expression analysis [2] and contract production of biologicals according to GMP guidelines.
Miltenyi Biotec technologies are used in applications concerned with accessing, analyzing, and utilizing primary and primary-derived cells – across basic research, translational research, and clinical applications.[3] Examples of these applications include sample preparation, cell separation, cell sorting, flow cytometry, molecular applications, cell culture up to GMP grade, preclinical imaging, clinical-grade cell preservation, and clinical-scale cell processing. The company’s reagents and devices are used primarily in the research areas of immunology, stem cell biology, neuroscience and cancer.[4]
Sample Preparation
Miltenyi Biotec offers instruments, tools and reagents to facilitate sample preparation.
Application areas
Miltenyi Biotec products are used commonly in the application areas of immunology, stem cell biology, neuroscience and cancer. Their products are used from basic research to clinical applications and are designed to support the successful translation of findings into practical applications that enhance human health and well being. Enabling translational research is a major mission of the company, as is advancing cellular therapy. The company’s products aim to support the development of cellular therapies and make cellular therapy a more viable reality for more patients.
History
- 1989 – Stefan Miltenyi invents magnetic-activated cell separation
- 1990 – Miltenyi Biotec patents MACS Technology
- 1992 – Miltenyi Biotec opens its U.S. subsidiary
- 1995 – Miltenyi Biotec opens its UK subsidiary
- 1998 – Miltenyi Biotec opens its France, Italy and Spain subsidiaries
- 2001 – Miltenyi Biotec opens its China location
- 2002 – Miltenyi Biotec acquires the plasma absorber technology developed by PlasmaSelect AG and markets the products under the trademark TheraSorb
- 2002 – Miltenyi Biotec opens its Australia subsidiary
- 2003 – Miltenyi Biotec opens its GMP facility in Teterow, Germany
- 2003 – Miltenyi Biotec opens its Japan and Singapore subsidiaries
- 2003 – Miltenyi Biotec acquires Memorec Biotec GmbH
- 2004 – Miltenyi Biotec opens its Benelux subsidiary in the Netherlands
- 2008 – Miltenyi Biotec acquires Medic Tools AG [5]
- 2008 – Miltenyi Biotec launches its autoMACS Pro Separator cell separation instrument
- 2008 – Miltenyi Biotec launches its MACSQuant Analyzer flow cytometry instrument
- 2011 – Miltenyi Biotec acquires Coley Pharmaceutical Group
- 2011 – Miltenyi Biotec partners with TeutoCell to develop novel cell culture techniques [6]
- 2012 – Miltenyi Biotec opens its Nordic subsidiary in Sweden
- 2012 – Miltenyi Biotec opens its Korea subsidiary in Seoul, South Korea
- 2013 – Miltenyi Biotec acquires Owl biomedical, adding to their portfolio new microchip-based cell sorting technology
- 2014 – Miltenyi Biotec receives FDA approval for CliniMACS® CD34 Reagent System for prevention of graft-versus-host disease in the treatment of acute myeloid leukemia
- 2014 – Miltenyi Biotec acquires gene therapy assets from Lentigen Corporation
- 2017 – Acquisition of imaging specialist Sensovation AG
- 2018 – Acquisition of microscopy specialist LaVision BioTec
Structure
Miltenyi Biotec is a limited liability company (referred to as GmbH in Germany). The officers of the company are Stefan Miltenyi (Founder and President), Dr. Boris Stoffel, Norbert Hentschel, Dr. Juergen Schmitz, Dr. Anoon Overstijns. Headquartered in Bergisch Gladbach with a GMP facility in Teterow, Germany, Miltenyi Biotec also has locations in the United States (two GMP facilities), Great Britain, France, Belgium, Italy, Spain, China, Australia, Japan, The Netherlands, Singapore and Sweden.
The company has more than 3,500 employees worldwide (approx. 800 in the United States).
The North American Divisions are supported by Miltenyi Biotec North America, which provides all central services to the North American Divisions.
Controversies
In March 2022, citing Russian Invasion of Ukraine as the reason,[7] Miltenyi Biotec suspended supplies of CAR-T therapy equipment to Russian Rogachev children's hospital, leaving patients with incurable tumors for which all other possibilities have been exhausted with no treatment options.[8] According to Alexei Maschan, director of the Institute of Hematology, Immunology and Cell Technologies of the National Medical Research Center, it will lead to their death.[9] While the treatment was available, 90% of child patients were achieving remission, with at least 54 survivors since 2018.[10]
References
- ^ "Browse antibodies by Miltenyi Biotec". CiteAb. Archived from the original on 11 September 2014. Retrieved 11 September 2014.
- ^ "Key Features in the Latest Flow Cytometry Systems, Caitlin Smith, Biocompare". Archived from the original on 2019-04-02. Retrieved 2013-01-14.
- ^ "Official website". Archived from the original on 2012-09-15. Retrieved 2013-01-14.
- ^ "Small But Mighty, Andreas Gruetzkau".
- ^ "PR Newswire". Archived from the original on 2016-03-04. Retrieved 2013-01-14.
- ^ "Life Sciences Germany, Stefan Northoff". Archived from the original on 2018-12-15. Retrieved 2013-01-14.
- ^ "BioCentury.com".
- ^ "BioCentury.com".
The voluntary boycott will leave Russian children who would have received CAR-T cancer therapy with no options, unless they can travel to another country.
- ^ "Russia Matters".
Therefore, right now about 50 children with blood cancer—patients of the Rogachev Institute—are doomed to die.
- ^ Maschan, M.; Caimi, P. F.; Reese-Koc, J.; Sanchez, G. P.; Sharma, A. A.; Molostova, O.; Shelikhova, L.; Pershin, D.; Stepanov, A.; Muzalevskii, Y.; Suzart, V. G.; Otegbeye, F.; Wald, D.; Xiong, Y.; Wu, D.; Knight, A.; Oparaocha, I.; Ferencz, B.; Roy, A.; Worden, A.; Kruger, W.; Kadan, M.; Schneider, D.; Orentas, R.; Sekaly, R. P.; De Lima, M.; Dropulić, B. (2021). "Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients". Nature Communications. 12 (1): 7200. Bibcode:2021NatCo..12.7200M. doi:10.1038/s41467-021-27312-6. PMC 8664838. PMID 34893603.
